NT-proBNP in Different Patient Groups of COPD: A Systematic Review and Meta-Analysis

References

• Yigit E, Manav A, Ture M, et al. The Impact of Septoplasty on Cardiopulmonary Functions in Patients With Nasal Septal Deviation: a Prospective Comprehensive Analysis of Echocardiographic Outcome and Serum N-Terminal Pro BNP Levels. J Craniofac Surg. 2022;33(1):35–40. doi:10.1097/SCS.0000000000007801
   PubMed Web of Science ®Google Scholar
• Rabe KF, Watz H. Chronic obstructive pulmonary disease. Lancet. 2017;389(10082):1931–1940.
   PubMed Web of Science ®Google Scholar
• André S, Conde B, Fragoso E, et al. COPD and cardiovascular disease. Pulmonology. 2019;25(3):168–176.
   PubMed Web of Science ®Google Scholar
• Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med. 1998;339(5):321–328.
   PubMed Web of Science ®Google Scholar
• Salerno D, Marik PE. Brain natriuretic peptide measurement in pulmonary medicine. Respir Med. 2011;105(12):1770–1775.
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Packer M, Desai AS, et al. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail. 2013;15(9):1062–1073.
   PubMed Web of Science ®Google Scholar
• Eindhoven JA, van den Bosch AE, Boersma E, et al. The usefulness of brain natriuretic peptide in simple congenital heart disease - A systematic review. Cardiol Young. 2013;23(3):315–324.
   PubMed Web of Science ®Google Scholar
• Fu S, Ping P, Wang F, et al. Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure. J Biol Eng. 2018;12:2.
   PubMed Web of Science ®Google Scholar
• Calzetta L, Orlandi A, Page C, et al. Brain natriuretic peptide: much more than a biomarker. Int J Cardiol. 2016;221:1031–1038.
   PubMed Web of Science ®Google Scholar
• Chaouat A, Naeije R, Weitzenblum E. Pulmonary hypertension in COPD. Eur Respir J. 2008;32(5):1371–1385.
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D42–50.
   PubMed Web of Science ®Google Scholar
• Ozdemirel TS, Ulaşli SS, Yetiş B, et al. Effects of right ventricular dysfunction on exercise capacity and quality of life and associations with serum NT-proBNP levels in COPD: an observational study. Anadolu Kardiyol Derg. 2014;14(4):370–377.
   PubMedGoogle Scholar
• Liu F, Zhang X, Du W, et al. Diagnosis values of IL-6 and IL-8 levels in serum and bronchoalveolar lavage fluid for invasive pulmonary aspergillosis in chronic obstructive pulmonary disease. J Investig Med. 2021;69(7):1344–1349.
   PubMed Web of Science ®Google Scholar
• Boschetto P, Campo I, Stendardo M, et al. Plasma sRAGE and N-(carboxymethyl) lysine in patients with CHF and/or COPD. Eur J Clin Invest. 2013;43(6):562–569.
   PubMed Web of Science ®Google Scholar
• Gulen ST, Eryilmaz U, Yilmaz M, et al. Left ventricular dysfunction in relation with systemic inflammation in chronic obstructive pulmonary disease patients. Korean J Intern Med. 2019;34(3):569–578.
   PubMed Web of Science ®Google Scholar
• Urban MH, Eickhoff P, Funk GC, et al. Increased brachial intima-media thickness is associated with circulating levels of asymmetric dimethylarginine in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:169–176.
   PubMed Web of Science ®Google Scholar
• Wang HY, Xu QF, Xiao Y, et al. Cardiac response and N-terminal-pro-brain natriuretic peptide kinetics during exercise in patients with COPD. Respir Care. 2011;56(6):796–799.
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
   PubMed Web of Science ®Google Scholar
• Antonelli M, Barbieri G, Donelli D. Effects of forest bathing (shinrin-yoku) on levels of cortisol as a stress biomarker: a systematic review and meta-analysis. Int J Biometeorol. 2019;63(8):1117–1134.
   PubMed Web of Science ®Google Scholar
• Liu Y, Liu X, Lin G, et al. Decreased CD34+ cell number is correlated with cardiac dysfunction in patients with acute exacerbation of COPD. Heart Lung Circ. 2014;23(9):875–882.
   PubMed Web of Science ®Google Scholar
• Huang YS, Feng YC, Zhang J, et al. Impact of chronic obstructive pulmonary diseases on left ventricular diastolic function in hospitalized elderly patients. Clin Interv Aging. 2015;10:81–87.
   PubMed Web of Science ®Google Scholar
• Weir-McCall JR, Liu-Shiu-Cheong PS, Struthers AD, et al. Disconnection of pulmonary and systemic arterial stiffness in COPD. Int J Chron Obstruct Pulmon Dis. 2018;13:1755–1765.
   PubMed Web of Science ®Google Scholar
• Cuthbert JJ, Kearsley JW, Kazmi S, et al. The impact of heart failure and chronic obstructive pulmonary disease on mortality in patients presenting with breathlessness. Clin Res Cardiol. 2019;108(2):185–193.
   PubMed Web of Science ®Google Scholar
• Patel AR, Kowlessar BS, Donaldson GC, et al. Cardiovascular risk, myocardial injury, and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;188(9):1091–1099.
   PubMed Web of Science ®Google Scholar
• Jiang GY, Li Q, Lv YX. Short-term treatment of irbesartan and hydrochlorothiazide decreases plasma N-terminal pro-brain natriuretic peptide levels in subjects with acute exacerbations of COPD. Int J Chron Obstruct Pulmon Dis. 2019;14:73–80.
   PubMed Web of Science ®Google Scholar
• Watz H, Waschki B, Boehme C, et al. Extrapulmonary effects of chronic obstructive pulmonary disease on physical activity: a cross-sectional study. Am J Respir Crit Care Med. 2008;177(7):743–751.
   PubMed Web of Science ®Google Scholar
• Hwang YI, Park G, Kwon S, et al. Correlation between NT-proBNP and pulmonary arterial pressure in COPD patients. Tuberc Respir Dis. 2007;63:346.
   Google Scholar
• Rubinsztajn R, Nasiłowski J, Przybyłowski T, et al. Przydatność oznaczania NT-proBNP w diagnostyce duszności u chorych na POChP.[Usefulness of NT-proBNP serum level in the diagnosis of dyspnea in COPD patients]. Pneumonol Alergol Pol. 2013;81(1):24–29. Polish.
   PubMedGoogle Scholar
• Ghobadi H, Aslani MR, Hosseinian A, et al. The Correlation of Serum Brain Natriuretic Peptide and Interleukin-6 with Quality of Life Using the Chronic Obstructive Pulmonary Disease Assessment Test. Med Princ Pract. 2017;26(6):509–515.
   PubMed Web of Science ®Google Scholar
• Labaki WW, Xia M, Murray S, et al. NT-proBNP in stable COPD and future exacerbation risk: analysis of the SPIROMICS cohort. Respir Med. 2018;140:87–93.
   PubMed Web of Science ®Google Scholar
• Andrijevic L, Milutinov S, Andrijevic I, et al. Association Between the Inflammatory Biomarkers and Left Ventricular Systolic Dysfunction in Patients with Exacerbations of Chronic Obstructive Pulmonary Disease. Balkan Med J. 2017;34(3):226–231.
   PubMed Web of Science ®Google Scholar
• Spannella F, Giulietti F, Cocci G, et al. Acute Exacerbation of Chronic Obstructive Pulmonary Disease in Oldest Adults: predictors of In-Hospital Mortality and Need for Post-acute Care. J Am Med Dir Assoc. 2019;20(7):893–898.
   PubMed Web of Science ®Google Scholar
• Li H, Zeng Z, Cheng J, et al. Prognostic Role of NT-proBNP for in-Hospital and 1-Year Mortality in Patients with Acute Exacerbations of COPD. Int J Chron Obstruct Pulmon Dis. 2020;15:57–67.
   PubMed Web of Science ®Google Scholar
• Rutten FH, Moons KG, Cramer MJ, et al. Recognising heart failure in elderly patients with stable chronic obstructive pulmonary disease in primary care: cross sectional diagnostic study. BMJ. 2005;331(7529):1379.
   PubMed Web of Science ®Google Scholar
• Khaletskaya AI, Kuznetsov AN, Bolshova YV, et al. Cardiac Biomarkers in Patients with Isolated and Combined Course of Chronic Obstructive Pulmonary Disease and Chronic Heart Failure. Sovremennye tehn med. 2018;10:130.
   Web of Science ®Google Scholar
• Karoli N, Borodkin A, Rebrov A. Features of the clinic and diagnosis of chronic heart failure in patients with chronic obstructive pulmonary disease. Kardiologiia. 2019;59:47–55.
   PubMed Web of Science ®Google Scholar
• Losip A, Pop D, Sitar-Taut A, et al. NT-proBNP and Uric acid levels correlate in patients with COPD and heart failure. Acta Med Mediterranea. 2018;34(1):189.
   Web of Science ®Google Scholar
• Kovacs G, Avian A, Bachmaier G, et al. Severe Pulmonary Hypertension in COPD: impact on Survival and Diagnostic Approach. Chest. 2022;162(1):202–212.
   PubMed Web of Science ®Google Scholar
• Zuo H, Xie X, Peng J, et al. Predictive Value of Novel Inflammation-Based Biomarkers for Pulmonary Hypertension in the Acute Exacerbation of Chronic Obstructive Pulmonary Disease. Anal Cell Pathol. 2019;2019:5189165.
   Web of Science ®Google Scholar
• Tian F, Song W, Wang L, et al. NT-pro BNP in AECOPD-PH: old biomarker, new insights-based on a large retrospective case-controlled study. Respir Res. 2021;22(1):321.
   PubMed Web of Science ®Google Scholar
• Marcun R, Stankovic I, Vidakovic R, et al. Prognostic implications of heart failure with preserved ejection fraction in patients with an exacerbation of chronic obstructive pulmonary disease. Intern Emerg Med. 2016;11(4):519–527.
   PubMedGoogle Scholar
• Koliev V, Sarapulova I, Ryabova L. Diagnosis of chronic heart failure in patients with chronic obstructive pulmonary disease. Kazan Medical Journal. 2019;100:530–536.
   Google Scholar
• Vyshnyvetskyy I, Kholopov L, Batashova-Halynska V. Clinical characteristics of the respiratory and cardiovascular systems in patients with combination of chronic obstructive pulmonary disease and heart failure. Zaporozhye Med J. 2017;1:65.
   Google Scholar
• Hilde JM, Skjørten I, Grøtta OJ, et al. Right ventricular dysfunction and remodeling in chronic obstructive pulmonary disease without pulmonary hypertension. J Am Coll Cardiol. 2013;62(12):1103–1111.
   PubMed Web of Science ®Google Scholar
• Nasir SA, Singh S, Fotedar M, et al. Echocardiographic Evaluation of Right Ventricular Function and its Role in the Prognosis of Chronic Obstructive Pulmonary Disease. J Cardiovasc Echogr. 2020;30(3):125–130.
   PubMed Web of Science ®Google Scholar
• Buchan A, Bennett R, Coad A, et al. The role of cardiac biomarkers for predicting left ventricular dysfunction and cardiovascular mortality in acute exacerbations of COPD. Open Heart. 2015;2(1):e000052.
   PubMedGoogle Scholar
• Hall C. NT-ProBNP: the mechanism behind the marker. J Card Fail. 2005;11(5 Suppl):S81–83.
   PubMed Web of Science ®Google Scholar
• Hopkins WE, Chen Z, Fukagawa NK, et al. Increased atrial and brain natriuretic peptides in adults with cyanotic congenital heart disease: enhanced understanding of the relationship between hypoxia and natriuretic peptide secretion. Circulation. 2004;109(23):2872–2877.
   PubMed Web of Science ®Google Scholar
• Casals G, Ros J, Sionis A, et al. Hypoxia induces B-type natriuretic peptide release in cell lines derived from human cardiomyocytes. Am J Physiol Heart Circ Physiol. 2009;297(2):H550–555.
   PubMed Web of Science ®Google Scholar
• Zysman M, Deslee G, Perez T, et al. Burden and Characteristics of Severe Chronic Hypoxemia in a Real-World Cohort of Subjects with COPD. Int J Chron Obstruct Pulmon Dis. 2021;16:1275–1284.
   PubMed Web of Science ®Google Scholar
• Ma KK, Ogawa T, de Bold AJ. Selective upregulation of cardiac brain natriuretic peptide at the transcriptional and translational levels by pro-inflammatory cytokines and by conditioned medium derived from mixed lymphocyte reactions via p38 MAP kinase. J Mol Cell Cardiol. 2004;36(4):505–513.
   PubMed Web of Science ®Google Scholar
• Shyam Prasad Shetty B, Chaya SK, Kumar VS, et al. Inflammatory Biomarkers Interleukin 1 Beta (IL-1β) and Tumour Necrosis Factor Alpha (TNF-α) Are Differentially Elevated in Tobacco Smoke Associated COPD and Biomass Smoke Associated COPD. Toxics. 2021;9(4):543.
   Web of Science ®Google Scholar
• Ko FW, Chan KP, Hui DS, et al. Acute exacerbation of COPD. Respirology. 2016;21(7):1152–1165.
   PubMed Web of Science ®Google Scholar
• Ritchie AI, Wedzicha JA. Definition, Causes, Pathogenesis, and Consequences of Chronic Obstructive Pulmonary Disease Exacerbations. Clin Chest Med. 2020;41(3):421–438.
   PubMed Web of Science ®Google Scholar
• Hillas G, Perlikos F, Tzanakis N. Acute exacerbation of COPD: is it the “stroke of the lungs”? Int J Chron Obstruct Pulmon Dis. 2016;11:1579–1586.
   PubMed Web of Science ®Google Scholar
• McDonald MN, Wouters EFM, Rutten E, et al. It’s more than low BMI: prevalence of cachexia and associated mortality in COPD. Respir Res. 2019;20(1):100.
   PubMedGoogle Scholar
• Pavasini R, Tavazzi G, Biscaglia S, et al. Amino terminal pro brain natriuretic peptide predicts all-cause mortality in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis. Chron Respir Dis. 2017;14(2):117–126.
   PubMed Web of Science ®Google Scholar
• Chang CL, Robinson SC, Mills GD, et al. Biochemical markers of cardiac dysfunction predict mortality in acute exacerbations of COPD. Thorax. 2011;66(9):764–768.
   PubMed Web of Science ®Google Scholar
• McCrory DC, Coeytaux RR, Schmit KM, et al. AHRQ Comparative Effectiveness Reviews. Pulmonary Arterial Hypertension: Screening, Management, and Treatment. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013.
   Google Scholar
• Cao Z, Jia Y, Zhu B. NT-proBNP as Diagnostic Biomarkers for Cardiac Dysfunction in Both Clinical and Forensic Medicine. Int J Mol Sci. 2019;20:548.
   PubMed Web of Science ®Google Scholar
• Karoli NA, Borodkin AV, Kosheleva NA, et al. Факторы риска развития неблагоприятных исходов у пациентов с хронической обструктивной болезнью легких и хронической сердечной недостаточностью[Prognostic markers for the development of adverse outcomes in patients with chronic obstructive pulmonary disease and chronic heart failure]. Kardiologiia. 2018;58(Suppl 9):39–47. Russian.
   PubMedGoogle Scholar